Open access

Evidence Based Guidelines for Preparation Before Upper Gastrointestinal Endoscopy (UGIE)

Written By

Arjuna P. De Silva

Submitted: 07 April 2011 Published: 21 November 2011

DOI: 10.5772/21914

From the Edited Volume

Gastrointestinal Endoscopy

Edited by Oliviu Pascu

Chapter metrics overview

4,724 Chapter Downloads

View Full Metrics

1. Introduction

Among the different conditions of critical illness leading to admission to an Intensive Care Unit (ICU), sepsis remains the leading cause of death at the non-coronary medical ICU [1]. Even with optimal therapy, mortality rates of severe sepsis and septic shock are about 40 to 50% [2, 3]. Although there are numerous studies with varying methods from different countries, the incidence of severe sepsis is constantly approximately one out of ten admissions to all ICUs worldwide [4]. With millions of individuals concerned every year, worldwide sepsis is one of the major healthcare problems today. The proportion of severe sepsis, and case fatal outcomes increased during the last years [2]. It is crucial to establish the diagnosis sepsis as early as possible and to identify its origin, in order to initiate an appropriate therapy permitting to achieve the best possible outcome [5].

Sepsis is defined as a systemic inflammatory response syndrome (SIRS) caused by an infection. The association with organ dysfunction or sepsis-induced hypotension is termed severe sepsis. Septic shock, as a subset of severe sepsis, is characterized by sepsis-induced hypotension, persisting despite adequate fluid resuscitation [6]. Early differentiation between sepsis and SIRS is a considerable problem in the treatment of patients on ICU. Due to the early systemic release of inflammatory cytokines as compared with synthesis of acute-phase-proteins, cytokines have been widely investigated for their diagnostic potential in predicting sepsis [7]. Nevertheless, until now the perfect biomarker for differentiation of sepsis and SIRS has not been found yet and ongoing research focuses on identification of appropriate diagnostic biomarkers for sepsis [8].

Despite a growing number of studies, the physiopathology of sepsis is not satisfyingly understood. Data show that physiopathology is characterized by a large number of pro- and anti-inflammatory cytokines and mediators of inflammation with complex interactions [9]. For instance, the application of a single bolus i.v. infusion of endotoxin to a healthy individual leads to the expression of 3147 genes, (> 10% of the human genome) [10]. These mediators and cytokines lead to endothelial dysfunction and activation of inflammatory and coagulation pathways as reaction to the invasion of a pathogen [11]. In order to reduce the sepsis-related high mortality, a better understanding of common pathogenic mechanisms of sepsis and other critical diseases is needed, potentially resulting in more effective treatment options.


2. Obesity in critical disease

At present, obesity is regarded as a low-grade proinflammatory state with oxidative stress caused by glucose and macronutrient intake. In this setting various proinflammatory cytokines and acute phase reactants are induced, e.g. TNF-α and IL-6, which are mainly derived from the macrophages as part of the white adipose tissue [11, 12]. Oxidative stress leads to the production of reactive oxygen species (ROS) with NADPH oxidase as major vascular source of ROS [13]. ROS are particularly important for endothelial dysfunction and can cause cellular injury [14]. For these reasons the reaction to sepsis in obese individuals is different than those in individuals without chronic inflammatory state [11].

Obesity has been suggested as a prominent risk factor for mortality in critically ill patients, especially in sepsis [15, 16]. Singer et al. hypothesized that continuous low-grade chronic inflammation primes blood and endothelial cells to reply more rapidly to any additional inflammatory stimulus, such as sepsis [17]. However, recent publications on critical disease, only reported an influence of obesity on morbidity, but not on mortality [18, 19]. This means that obese and very obese patients acquired more frequently ICU-associated infections and had a longer length-of-stay, but there was no evidence for a higher 60-day in-hospital mortality compared with normal weighted patients in the study of Sakr et al. [19].


3. Hyperglycemia and insulin resistance in critical disease

As in obesity, hyperglycemia, impaired glucose tolerance and insulin resistance are common findings in critically ill patients after surgery or with sepsis [20]. This feature has also been termed “diabetes of injury” [21, 22]. Hyperglycemia in hospitalized patients is known to lead to various adverse effects (e.g. fluid imbalance, alterations of immune function and inflammation), which are commonly improved by glucose control [23] (Table).

Adverse effects of Acute Hyperglycemia
Blood-flow abnormalities
Increase of vascular permeability
Electrolyte disturbances
Fluid shifts
Acid-base disturbances
Proinflammatory gene expression
Immune dysfunction
Impairment of complement activity
Inhibition of opsonization

Table 1.

Adverse effects of Acute Hyperglycemia in critical illness (modified from [23])

In case of critical disease or trauma hepatic gluconeogenesis is increasing despite hyperglycemia and high insulin levels, whereas insulin-dependent glucose uptake in skeletal muscle and heart is impaired. In critically ill patients the overall glucose-uptake is elevated but mainly in tissues which do not depend on insulin for glucose uptake [24]. Hyperglycemia in critically ill patients has been related to mediators of stress, but there is growing evidence for causative defects in glucose metabolism [25] (Fig.1). Moreover, proinflammatory cytokines can affect glucose metabolism by changing insulin receptor signaling and by boosting counterregulatory hormone secretion [21, 26]. Likely, adipocytokines link hyperglycemia and insulin resistance to inflammation in sepsis.

Figure 1.

Etiology of acute hyperglycemia. Acute stress response is characterized by complex interactions of counter-regulatory hormones, cytokines and insulin sensitivity (modified from [23]).

In 2001 a milestone study from van den Berghe et al. showed that tight control of hyperglycemia during critical illness in a cohort of cardiac surgery patients significantly improved outcome in terms of morbidity and mortality. Adjustment of hyperglycemia resulted in less severe nosocomial infections, renal and hepatic dysfunction, critical illness polyneuropathy, muscle weakness, and anemia [27, 28]. Increasing hyperglycemia paralleled increase in rates of mortality in critical illness [27]. Nevertheless, consecutive studies in medical ICU patients demonstrated higher mortality for intensive insulin therapy, potentially due to severe hypoglycemia [29]. Therefore, control of hyperglycemia by insulin therapy in a moderate range of blood glucose levels of 140-180 mg/dL is at present part of standard therapy in critically ill patients.


4. Adipose tissue as a hormonally active organ

Historically, adipose tissue was solely considered to store excess energy. Most recent data emphasize the role of adipose tissue as a hormonally active system, influencing inflammation, metabolism, body weight, and lipid and glucose metabolism [30]. Proteins mainly secreted by adipocytes are called adipokines [11]. Matsuzawa and colleagues reported that approximately 30% of all genes expressed in visceral fat encode secretory proteins [31]. An increasing number of soluble mediators (“adipocytokines”) mainly derived from adipocytes itself or other cell types from adipose tissue (e.g. stromavascular fraction, adipose precursor cells and macrophages in the adipose tissue) have been identified. Adipocytokines are important mediators linking chronic inflammatory conditions to systemic insulin resistance in obesity and diabetes mellitus type 2 [18, 32] (Fig.2).

Figure 2.

Secretion of adipocytokines and ‘classic’ inflammatory cytokines by white adipose tissue. Although regarded as an adipokine resistin is in humans mainly derived from macrophages. TNF, tumor necrosis factor; IL, interleukin; NF, nuclear factor (modified from [11]).

Potentially relevant factors released from fat tissue include hormones, adipocytokines, chemokines, growth factors, transcription factors, enzymes and participants of the coagulation cascade [33]. Many of these factors signal to organs of metabolic importance and the immune system and thus contribute to the phenomenon of insulin resistance [30] as proved for TNF-α and IL-6 [34, 35]. A recent study demonstrated similar high adipocytokine profiles in septic patients as well as in morbidly obese [36]. Most validated data are available for Interleukins-1,-6,-8 and -10, TNF-α, Resistin, Adiponectin, Leptin, Leptin-Rezeptor, RBP4, Osteopontin, Visfatin, Omentin, Adipsin, Sfrp5, Adipophilin and VASPIN (visceral adipose-tissue-derived serine protease inhibitor).

In critically ill patients adipocytokines seem to be involved in the regulation of inflammation and metabolism and by this directly influence the clinical outcome of ICU patients. For critical illness, especially severe sepsis and septic shock, most valid data are available for resistin, leptin, leptin-receptor, and adiponectin.


5. Resistin

Up to now, resistin is the most widely studied adipocytokine in critical illness. Human resistin is mainly derived from macrophages and neutrophils as recently reported [37] and not from adipocytes (like in mice [38]) and has been implicated in glucose metabolism and insulin sensitivity. It is named for mediating resistance to insulin through the exacerbation of the adipose tissue inflammation in humans [39]. In a knock-out mouse model it has been demonstrated that the lack of resistin protects against diet-induced insulin resistance and type 2 diabetes mellitus [40].

Elevated resistin serum levels have been found in critically ill patients with significantly higher concentrations in sepsis than in non-sepsis patients and peak values in septic shock [37, 41]. Likely, resistin seems to act as an acute-phase protein and might be part of the systemic inflammatory response, as it has been correlated to IL-6, IL-10, TNF-α, C-reactive protein and procalcitonin [42].

Data concerning the correlation between resistin, obesity, insulin resistance, hyperglycemia and diabetes mellitus are controversially discussed at present. Several studies found a positive correlation between resistin serum levels and hyperinsulinemia, hyperglycemia and insulin resistance in patients who suffer from obesity and type 2 diabetes [43, 44], but these findings could not be confirmed in other studies [45, 46]. Interestingly, resistin levels have been recently found to be independent of pre-existing diabetes mellitus or body-mass index (BMI) in critically ill, especially in septic patients [41, 42].

Resistin serum levels have been correlated to renal and liver functions [47, 48], implicating renal and hepatic elimination or degradation of resistin. Resistin is considered as a part of the systemic inflammatory response from adipocytes, but in the critical illness response, resistin seems to be mainly derived from macrophages and not from adipocytes [42].

For critically ill, non-septic patients, high resistin serum concentrations have been identified as an adverse prognostic indicator for the ICU- as well as overall survival. Potentially, high resistin levels could indicate an excess of inflammatory reaction that might be of considerable harm, even in the absence of infection [42].


6. Leptin and leptin-receptor

Since its identification in 1994 leptin has been known for its role in controlling body weight and food intake through hypothalamic pathways [49, 50]. The name leptin derived from the Greek language, as the word leptos means thin [51]. In mouse models, deficiency of leptin or leptin-receptor resulted in a hyperphagic, morbidly obese, and lethargic phenotype with significantly reduced macrophage phagocytic activity [52-54]. Circulating leptin levels directly reflect adipose tissue mass in non-critically ill subjects [55]. The same result applies in critical disease, in which leptin has also been found to closely correlate with adipose tissue mass; moreover, an inverse association between circulating leptin-receptor and the BMI in critically ill patients has been reported [56].

Little is known about the mechanisms of leptin expression. It is secreted not only from white adipocytes, but also from placenta and stomach [57]. In not critically ill individuals leptin serum concentrations correlate with impaired insulin sensitivity, increased inflammatory markers, and coronary artery disease [58]. Various central and peripheral effects of leptin via leptin-receptors in brain and leptin-receptors in pancreas, liver, adipose tissue, and in the immune system, especially in human peripheral blood mononuclear cells, have been described [59]. Therefore, leptin is not only involved in control of body weight and energy expenditure, but also in glucose homeostasis and immunoregulation. Leptin is able to modulate the immune response by proliferation and activation of the mononuclear cells. Moreover, it activates the production of proinflammatory cytokines in cultured monocytes, protects monocytes against apoptosis and influences RNA metabolism. The leptin-receptor itself is similar to members of the class I cytokine family and exists in six isoforms [60]. Leptin is regarded as a proinflammatory cytokine itself [61], whose action in the central nervous system is necessary for an adequate systemic immune response [62].

In animal and human studies administration of endotoxin and TNF-α as inducers of severe systemic inflammation resulted in significant elevation of serum leptin levels [63]. Yousef and colleagues also reported increased values for IL-6, CRP, TNF-α and leptin at admission to ICU, with leptin threshold values of 38 µg/l for distinguishing between SIRS and sepsis [7]. Controversially, among other studies, a study from Denmark revealed low leptin levels - and also low adiponectin and RBP4 levels - at admission to the ICU, possibly due to an acute stress response [64]. The absence of increasing leptin levels in these studies may be due to the short duration of the experiments, given that a delay is needed to observe an increase of leptin following a LPS-stimulation [65]. Another study in critically ill patients, including septic and non-septic groups didn’t report differences in leptin and leptin-receptor serum concentrations as compared with healthy controls [56].

Besides the suggested potential role as a diagnostic parameter leptin and leptin-receptor seem to have a prognostic impact, as high leptin-receptor serum concentrations at admission to ICU have been identified as an adverse prognostic indicator for survival [56]. Bornstein and colleagues noticed earlier that low levels of leptin might indicate a poor prognosis in septic patients [66]. Other studies had similar findings with exogenous leptin administration as a protective factor in leptin-deficient mice [67, 68]. These results are in conflict with observations from other investigators. Shapiro et al. reported a decrease in survival rates after application of exogenous leptin in murine sepsis models, whereas leptin-receptor deficient mice showed a better outcome with higher survival rates [60].

Despite the strong evidence that leptin takes part in the cell-mediated immunity response and in cytokine crosstalk [69] additional studies for clearing the role of leptin and its receptors in sepsis and SIRS are warranted.


7. Adiponectin

Adiponectin is the most abundant adipocytokine in humans with high serum concentrations, normally accounting for about 0.01% of total plasma protein [70]. There are three different molecular forms of circulating adiponectin [30]. It is exclusively secreted by adipocytes with higher serum concentration in females [71]. Interestingly, despite sole adipocytic origin, adiponectin has been found to be inversely correlated to the BMI in healthy individuals and in critically ill patients as well [72]. Until now, this so called “adiponectin paradox” – exclusive synthesis in adipocytes but low adiponectin levels in obesity - has not been solved yet [73]. Secretion of adiponectin is boosted several folds by insulin [70], but interestingly in type 2 diabetes - as in obesity - adiponectin serum concentrations are reduced [74]. Reduced adiponectin levels and an association with pre-existing diabetes mellitus have been reported in critically ill patients as well [72].

Adiponectin has been found as an anti-atherogenic agent with positive correlation to high-density lipoprotein cholesterol and inverse correlations to low-density lipoprotein cholesterol, triglycerides, insulin resistance, and diastolic blood pressure. Moreover, adiponectin seems to exert direct anti-atherogenic effects on the endothelial cells [75]. Studies in rodents also demonstrated protective functions of adiponectin in obesity and insulin resistance [76]. In a study with nondiabetic, but obese patients with varying degrees of insulin resistance, the presence of adiponectin resulted in an increase of insulin-sensitivity. Concomitantly to higher adiponectin serum concentrations in lean individuals, serum levels of TNF-α are decreased [74]. As TNF-α is presently known for its implication in insulin resistance, reduced serum concentrations might affect higher insulin sensitivity as well [77].

Additionally, adiponectin seems to have anti-inflammatory functions in animal models of sepsis. It has been reported as a potent inhibitor of cytokine production in porcine macrophages [78]. Furthermore, adiponectin-knockout mice had significantly higher mortality rates and serum levels of inflammatory markers in polymicrobial sepsis [79]. In a study of Teoh and colleagues the administration of adiponectin to adiponectin-knockout mice led to an improved outcome in experimentally generated sepsis. As concluded by the authors, low adiponectin levels potentially link obesity and the (discussed) worse outcome of obese patients in sepsis [80]. Glucocorticoids, inflammation, and oxidative stress – commonly associated with critical disease – are known for reducing adiponectin synthesis [81]. Matching these facts, some studies reported low adiponectin levels in patients with critical disease of pulmonary origin and also in rats with sepsis (without analyzing the impact of the measured low values on mortality or outcome) [64, 82]. Nevertheless, there are conflicting data concerning the role of adiponectin in critical illness. In a large monocenter clinical study there was no difference in adiponectin serum levels in critically ill patients compared to healthy controls and furthermore no difference between septic and non septic patients. In the same study low adiponectin serum concentrations at admission to ICU have been found as a positive prognostic indicator for ICU and overall survival in contrast to the above mentioned theory of low adiponectin levels worsening the outcome of critically ill patients [72].

Interestingly, no correlation of adiponectin with cytokines or mediators of inflammation have been reported in critically ill patients [64, 72]. The mechanisms of adiponectin excretion and biodegradation in critical disease are presently unclear. Due to a reported correlation between adiponectin levels and markers of cholestasis and cystatin C as a marker of renal function, hepatic and renal elimination have been discussed in critically ill patients [72]. Other studies in non-ICU patients with liver cirrhosis, animal models and uremic patients confirm the theory of partially biliary and renal excretion of adiponectin [83, 84]. Yuan et al. reported a direct suppression of adiponectin gene expression by C-reactive protein in a concentration- and time-dependent manner [85], which might be an important finding for understanding adiponectin in critical disease, especially in sepsis, in which extremely high CRP levels are frequently found.

As a result of the entirety of conflicting data, up to now it remains unclear whether circulating adiponectin is pathogenetically involved in mechanisms of critical disease leading to higher mortality rates. Maybe it is an epiphenomenon of variables such as adiposity, yet unknown functions of adipose tissue or metabolic alterations in critical illness [72].


8. Retinol binding protein 4 (RBP4)

Retinol binding protein 4 is secreted by adipose tissue and liver. Although it is named an adipocytokine for its derivation of adipocytes, the main source of RBP4 in humans is the liver [86]. Besides serving as a transport protein for vitamin A (retinol), RBP4 has been implicated in the development of insulin resistance in rodent models and in humans [87, 88]. Von Eynatten et al. found elevated gene expression for RBP4 in the adipose tissue, but not in the liver of insulin-resistant mice, whereas the application of RBP4 to other mice led to insulin resistance [87]. Another study demonstrated down-regulation of the insulin-responsive glucose-transporter GLUT4 in adipocytes in obesity, resulting in increased secretion of RBP4 by a yet unknown regulatory mechanism [88]. RBP4 has been identified as a marker of insulin resistance in individuals with various clinical presentations, but not yet manifested diabetes mellitus. The strong correlation to insulin resistance in case of obesity, impaired glucose tolerance, type 2 diabetes and even in lean subjects seems to be more specific than the correlation of other adipocytokines like leptin and adiponectin to insulin resistance [89].

As a consequence of its main derivation from the liver, RBP4 serum levels are reduced in case of chronic and acute liver diseases or dysfunction [86, 90]. But also renal function seems to be important for the RBP4 metabolism with increasing levels in case of impaired renal function [91].

In critical disease RBP4 serum levels have been found decreased compared to healthy controls, independent of the origin of critical illness [64, 92]. During the course of disease, serum levels normalized with resolving critical illness [64]. Langouche and colleagues hypothesized that reduced synthesis or increased removal might be the reason for the decreased serum levels. In sepsis, capillary leakage has been considered as a possible mechanism for reducing the levels of adipocytokines in general [64]. As shown in another study the decrease in serum concentrations of RBP4 is independent of the origin of critical illness. There was no difference between concentrations in septic and non-septic patients requiring intensive care medicine, so capillary leakage as a well-known problem in sepsis seems not to be the main reason [92]. Instead, a strong correlation between liver and kidney function and serum RBP4 concentrations was found, reflecting the above mentioned relation of RBP4 to liver and kidney function observed in not critically ill patients [92]. As RBP4 levels were inversely correlated with markers of inflammation, RBP4 seems potentially to be a member of the negative acute-phase reactants described by Richie et al. [93], what might be another explanation for decreased levels in critical disease [92]. At present, no association between RBP4 and other adipokines like adiponectin and resistin has been reported, suggesting that the adipose tissue does not contribute to a great extent to serum RBP4 concentrations in critical disease [92].

Recently, despite a missing association of RBP4 with preexisting diabetes mellitus or obesity, a study reported a correlation with C-peptide levels, reflecting endogenous insulin production, and with insulin resistance (HOMA index) [92]. The hypothesis of RBP4 interaction in glucose metabolism is supported by a recent finding, that during intensive insulin therapy the raise of RBP4 levels in the course of critical illness is blunted [64].

Importantly, high serum concentrations of RBP4 at admission to the ICU have been identified as a positive predictor of ICU-survival [92]. Maybe this is due to the fact that higher RBP4 levels just represent preserved liver function and are not pathogenetically involved in the course of critical disease, as liver function itself is clearly linked to survival rates in critical disease [94]. Further studies are needed to definitely clarify the regulatory pathways of RBP4, its role in the pathogenesis of critical illness, and its significance as a potential novel biomarker for ICU patients.


9. Visfatin

Initially known as Pre-B-cell colony-enhancing factor (PBEF) this recently described adipocytokine was found in high concentrations in visceral fat, therefore renamed visfatin [95]. The third name for this eclectic protein is Nampt (nicotinamide phosphoribosyltransferase) [96]. Interestingly, visfatin has a unique structure without homology to other known proteins [96]. The number of names already indicates the divers properties exerted by this protein.

As Nampt, this protein acts intracellular as the rate-limiting part of the NAD (nicotinamide adenine dinucleotide) production in mice [97]. NAD is an essential cofactor in numerous fundamental intracellular processes [98]. Moreover Kitani et al. proposed a role for PBEF in cell cycle regulation because of its varying intracellular distribution due to the growth phase of the cell [99].

As characteristic for adipocytokines visfatin is involved in the glucose metabolism. By binding to the insulin-receptor it shows insulin-mimetic effects in mice and cultured cells [100]. In question of reproducibility of these effects of visfatin, this publication had to be retracted recently [101], but Xie et al. demonstrated an insulin-like effect of visfatin on cultured osteoblasts [102]. Furthermore, other authors reported a correlation between visfatin serum levels and obesity, diabetes mellitus, and visceral fat mass [103-105]. Therefore, visfatin seems to be involved in a number of metabolic processes, but the definite role remains to be clarified.

Initially PBEF was discovered by Samal et al. (1994) as a mediator of maturation of B-cells precursors, secreted by activated lymphocytes in bone marrow stromal cells. Its gene was found mainly transcribed in human bone marrow, liver tissue, and muscle [106]. Even though the characteristic signal peptide required for extracellular secretion of mature protein is missing, PBEF shows other properties which allow allocation of it to the class of cytokines [106]. PBEF has been found as an inhibitor of apoptosis of neutrophils in experimental inflammation and clinical sepsis by Jia et al. [107]. The excess of neutrophils in sepsis accounts for inflammatory tissue damage, e.g. for respiratory distress syndromes as often observed in sepsis [108]. The prolonged survival of neutrophils in sepsis due to inhibition of apoptosis mediated by PBEF even amplifies these destructive effects [107]. Furthermore increased PBEF was found in swollen or infected human fetal membranes indicating cytokine functions [109]. It exerts chemotactic activity and up-regulates the serum levels of other pro-inflammatory cytokines [110]. Garcia and Vinasco demonstrated a crucial role for PBEF in acute lung injury (ALI), which is usually caused by sepsis [111]. In these critical ill patients they found elevated concentrations of PBEF in bronchoalveolar lavage and serum. They identified two single nucleotide polymorphisms in the PBEF promoter, which seems to enhance the susceptibility for the development of ALI in septic patients.

Although the role of PBEF as a cytokine is incompletely understood today, this protein seems to have a magnitude of properties contributing to the complex mechanisms accounting for the course of critical disease. Not at least this is underlined by the fact that PBEF is highly conserved through evolution as it could be identified in bacteria [112], invertebrate sponges [113], fishes [114], chickens and mammals [115].


10. Adipsin

When adipsin was initially identified in 1983, this was the first evidence for the potential role of adipose tissue in regulation of immune system biology [116]. Spiegelman and colleagues discovered adipsin mRNA in cultured mouse adipocyte cell lines [117]. Just a short time after its identification the similarity between the novel serin protease adipsin in mice and human complement factor D was shown [118]. Factor D is a serin protease accounting for the activation of the alternative pathway of complement activation. It constitutes the initial obligatory, rate-limiting catalytic activity of this activation by cleaving complement factor B when B is complexed with an activated form of complement component C3 [119]. The complement system is the key in innate immunity with important properties in enhancing adaptive immunity and in the clearance of bacteria and apoptotic cells [120]. In dissimilarity to mouse adipsin, which is only expressed by adipose tissue, human complement factor D it mainly derived from macrophages and monocytes [121]. So the potential involvement of this adipocytokine in critical disease seems obvious. Adipsin-deficiency abolishes alternative-pathway dependent complement activation, in case of infection with Neisseria meningitidis leading to an increased susceptibility for invasive meningococcal disease [122, 123].

Adipsin also seems to play an important role in energy balance as it has been found to be decreased in fat from genetically obese and diabetic mice in comparison to normal lean mice and also in serum levels of varying animal models in obesity [124, 125]. Its serum concentrations decline during infusion of glucose which results in a hyperglycemic and hyperinsulinemic state [124]. Interestingly, the serum adipsin concentrations are reduced in case of genetically and chemical induced obesity, whereas in the state of adiposity resulting from pure overfeeding there is no change leading to the conclusion that adipsin could be a marker for distinguishing between obesity caused by metabolic disorders or caused just by overfeeding [124].

11. Conclusion

Overall, adipocytokines in critical illness seem to fulfill various functions which are at present not satisfyingly understood. The interaction of metabolic and inflammatory mediators has been found of prognostic impact in these patients. More and more functions of adipocytokines and their interaction in insulin resistance, obesity and immune reactions have been unraveled by an increasing number of clinical and animal studies. Nevertheless, further future research is crucial to understand the complex effects of adipocytokines and their role as a link between inflammation and metabolism in critical disease.


  1. 1. Angus D. C. Linde-Zwirble W. T. Lidicker J. Clermont G. Carcillo J. Pinsky M. R. 2001 Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29 7 1303 1310 .
  2. 2. Dombrovskiy V. Y. Martin A. A. Sunderram J. Paz H. L. 2007 Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med, 35 5 1244 1250 .
  3. 3. Vincent J. L. Sakr Y. Sprung C. L. Ranieri V. M. Reinhart K. Gerlach H. Moreno R. Carlet J. Le Gall J. R. Payen D. 2006 Sepsis in European intensive care units: results of the SOAP study. Crit Care Med, 34 2 344 353 .
  4. 4. Linde-Zwirble W. T. Angus D.C. 2004 Severe sepsis epidemiology: sampling, selection, and society. Crit Care, 8 4 222 226 .
  5. 5. Claus R.A, Otto G.P, Deigner H.P, Bauer 2010 2010. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med, 10 2 227 235 .
  6. 6. Bone R. C. Balk R. A. Cerra F. B. Dellinger R. P. Fein A. M. Knaus W. A. Schein R. M. Sibbald W. J. 1992 Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.. Chest 2009, 136(5 Suppl):e28.
  7. 7. Yousef A. A. Amr Y. M. Suliman G.A. 2010 The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. Crit Care, 14(2):R33.
  8. 8. Pierrakos C. Vincent J.L. 2010 Sepsis biomarkers: a review. Crit Care, 14(1):R15.
  9. 9. Cavaillon J. M. Adib-Conquy M. Fitting C. Adrie C. Payen D. 2003 Cytokine cascade in sepsis. Scand J Infect Dis, 35 9 535 544 .
  10. 10. Calvano S. E. Xiao W. Richards D. R. Felciano R. M. Baker H. V. Cho R. J. Chen R. O. Brownstein B. H. Cobb J. P. Tschoeke S. K. et al. 2005A network-based analysis of systemic inflammation in humans. Nature, 437 7061 1032 1037 .
  11. 11. Vachharajani V. Vital S. 2006 Obesity and sepsis. J Intensive Care Med, 21 5 287 295 .
  12. 12. Dandona P. Aljada A. Bandyopadhyay A. 2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol, 25 1 4 7 .
  13. 13. Furukawa S. Fujita T. Shimabukuro M. Iwaki M. Yamada Y. Nakajima Y. Nakayama O. Makishima M. Matsuda M. Shimomura I. 200 I. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 114 12 1752 1761 .
  14. 14. Cooper D. Stokes K. Y. Tailor A. Granger D. N. 2002 Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol, 2 3 165 180 .
  15. 15. El -Solh A. Sikka P. Bozkanat E. Jaafar W. Davies J. 2001 Morbid obesity in the medical ICU. Chest, 120 6 1989 1997 .
  16. 16. Bercault N. Boulain T. Kuteifan K. Wolf M. Runge I. Fleury J. C. 2004 Obesity-related excess mortality rate in an adult intensive care unit: A risk-adjusted matched cohort study. Crit Care Med, 32 4 998 1003 .
  17. 17. Singer G. Granger D. N. 2007 Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirculation, 14(4-5):375 387 .
  18. 18. Akinnusi M. E. Pineda L. A. El Solh A. A. 2008 Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med, 36 1 151 158 .
  19. 19. Sakr Y. Madl C. Filipescu D. Moreno R. Groeneveld J. Artigas A. Reinhart K. Vincent J. L. 2008 Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med, 34 11 1999 2009 .
  20. 20. Van Cromphaut S. J. Vanhorebeek I. Van den Berghe G. 2008 Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des, 14 19 1887 1899 .
  21. 21. Mc Cowen K. C. Malhotra A. Bistrian B. R. 2001 Stress-induced hyperglycemia. Crit Care Clin, 17 1 107 124 .
  22. 22. Thorell A. Nygren J. Ljungqvist O. 1999 Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care, 2 1 69 78 .
  23. 23. Kovalaske M. A. Gandhi G.Y. 2009 Glycemic control in the medical intensive care unit. J Diabetes Sci Technol, 3 6 1330 1341 .
  24. 24. Van den Berghe. G. 2004 How does blood glucose control with insulin save lives in intensive care? J Clin Invest, 114 9 1187 1195 .
  25. 25. Falciglia 2007 2007. Causes and consequences of hyperglycemia in critical illness. Curr Opin Clin Nutr Metab Care, 10 4 498 503 .
  26. 26. Marette A. 2002 Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care, 5 4 377 383 .
  27. 27. Krinsley J.S. 2003Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc, 78 12 1471 1478 .
  28. 28. van den Berghe. G. Wouters P. Weekers F. Verwaest C. Bruyninckx F. Schetz M. Vlasselaers D. Ferdinande P. Lauwers P. Bouillon R. 2001 Intensive insulin therapy in the critically ill patients. N Engl J Med, 345 19 1359 1367 .
  29. 29. Finfer S. Chittock D. R. Su S. Y. Blair D. Foster D. Dhingra V. Bellomo R. Cook D. Dodek P. Henderson W. R. et al. 2009 Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 360 13 1283 1297 .
  30. 30. Badman M. K. Flier J.S. 2007 The adipocyte as an active participant in energy balance and metabolism. Gastroenterology, 132 6 2103 2115 .
  31. 31. Matsuzawa Y. Shimomura I. Kihara S. Funahashi T. 2003 Importance of adipocytokines in obesity-related diseases. Horm Res, 60 Suppl 3 56 59 .
  32. 32. Shoelson S. E. Herrero L. Naaz A. 2007 Obesity, inflammation, and insulin resistance. Gastroenterology, 132 6 2169 2180 .
  33. 33. Fantuzzi G. Mazzone T. 2007 Adipose tissue and adipokines in health and disease. Totowa, NJ: Humana Press Inc.;.
  34. 34. Hotamisligil G. S. Murray D. L. Choy L. N. Spiegelman B. M. 1994 Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A, 91 11 4854 4858 .
  35. 35. Klover P. J. Clementi A. H. Mooney R. A. 2005 Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology, 146 8 3417 3427 .
  36. 36. Hillenbrand A. Knippschild U. Weiss M. Schrezenmeier H. Henne-Bruns D. Huber-Lang M. Wolf A. M. 2010 Sepsis induced changes of adipokines and cytokines- septic patients compared to morbidly obese patients. BMC Surg, 10:26.
  37. 37. Johansson L. Linner A. Sunden-Cullberg J. Haggar A. Herwald H. Lore K. Treutiger C. J. Norrby-Teglund A. 2009 Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. J Immunol, 183 6 4047 4054 .
  38. 38. Savage D. B. Sewter C. P. Klenk E. S. Segal D. G. Vidal-Puig A. Considine R. V. O’Rahilly S. 2001 Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes, 50 10 2199 2202 .
  39. 39. Qatanani M. Szwergold N. R. Greaves D. R. Ahima R. S. Lazar M. A. 2009 Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest.
  40. 40. Banerjee R. R. Rangwala S. M. Shapiro J. S. Rich A. S. Rhoades B. Qi Y. Wang J. Rajala M. W. Pocai A. Scherer P. E. et al. 2004 Regulation of fasted blood glucose by resistin. Science, 303 5661 1195 1198 .
  41. 41. Sunden-Cullberg J. Nystrom T. Lee M. L. Mullins G. E. Tokics L. Andersson J. Norrby-Teglund A. Treutiger C. J. 2007 Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med, 35 6 1536 1542 .
  42. 42. Koch A. Gressner O. A. Sanson E. Tacke F. Trautwein C. 2009 Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care, 13(3):R95.
  43. 43. Mc Ternan P. G. Fisher F. M. Valsamakis G. Chetty R. Harte A. Mc Ternan C. L. Clark P. M. Smith S. A. Barnett A. H. Kumar S. 2003 Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab, 88 12 6098 6106 .
  44. 44. Fujinami A. Obayashi H. Ohta K. Ichimura T. Nishimura M. Matsui H. Kawahara Y. Yamazaki M. Ogata M. Hasegawa G. et al. 2004 Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta, 339(1-2):57 63 .
  45. 45. Pfutzner A. Langenfeld M. Kunt T. Lobig M. Forst T. 2003 Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab, 49(11-12):571 6 .
  46. 46. Stejskal D. Adamovska S. Bartek J. Jurakova R. Proskova J. 2003, Resistin- concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 147 1 63 69 .
  47. 47. Axelsson J. Bergsten A. Qureshi A. R. Heimburger O. Barany P. Lonnqvist F. Lindholm B. Nordfors L. Alvestrand A. Stenvinkel P. 2006 Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int, 69(3):596-604.
  48. 48. Yagmur E. Trautwein C. Gressner A. M. Tacke F. 2006 Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol, 101 6 1244 1252 .
  49. 49. Friedman J. M. Halaas J. L. 1998 Leptin and the regulation of body weight in mammals. Nature, 395 6704 763 770 .
  50. 50. Zhang Y. Proenca R. Maffei M. Barone M. Leopold L. Friedman J. M. 1994 Positional cloning of the mouse obese gene and its human homologue. Nature, 372 6505 425 432 .
  51. 51. Sone M. Osamura R. Y. 2001 Leptin and the pituitary. SoneM.OsamuraR. Y. 2001. Leptin and the pituitary. Pituitary, 4(1-2):15-23., 4(1-2):15 23 .
  52. 52. Considine R. V. Caro J. F. 1997 Leptin and the regulation of body weight. Int J Biochem Cell Biol, 29 11 1255 1272 .
  53. 53. Houseknecht K. L. Baile C. A. Matteri R. L. Spurlock M. E. 1998 The biology of leptin: a review. J Anim Sci, 76 5 1405 1420 .
  54. 54. Loffreda S. Yang S. Q. Lin H. Z. Karp C. L. Brengman M. L. Wang D. J. Klein A. S. Bulkley G. B. Bao C. Noble P. W. et al. 1998 Leptin regulates proinflammatory immune responses. FASEB J, 12 1 57 65 .
  55. 55. Havel P. J. Kasim-Karakas S. Mueller W. Johnson P. R. Gingerich R. L. Stern J. S. 1996 Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab, 81 12 4406 4413 .
  56. 56. Koch A. Weiskirchen R. Zimmermann H. W. Sanson E. Trautwein C. Tacke F. 2010 Relevance of serum leptin and leptin-receptor concentrations in critically ill patients. Mediators Inflamm, pii: 473540
  57. 57. Leininger M. T. Portocarrero C. P. Bidwell C. A. Spurlock M. E. Houseknecht K. L. 2000 Leptin expression is reduced with acute endotoxemia in the pig: correlation with glucose, insulin, and insulin-like growth factor-1 (IGF-1). J Interferon Cytokine Res, 20 1 99 106 .
  58. 58. Wallace A. M. Mc Mahon A. D. Packard C. J. Kelly A. Shepherd J. Gaw A. Sattar N. 2001 Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation, 104 25 3052 3056 .
  59. 59. Bjorbaek C. Kahn B.B. 2004 Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res, 59 305 331 .
  60. 60. Shapiro N. I. Khankin E. V. Van Meurs M. Shih S. C. Lu S. Yano M. Castro P. R. Maratos-Flier E. Parikh S. M. Karumanchi S. A. etal 2010 Leptin exacerbates sepsis-mediated morbidity and mortality. J Immunol, 185 1 517 524 .
  61. 61. Sanchez-Margalet V. Martin-Romero C. Santos-Alvarez J. Goberna R. Najib S. Gonzalez-Yanes C 2003 Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol, 133 1 11 19 .
  62. 62. Tschop J. Nogueiras R. Haas-Lockie S. Kasten K. R. Castaneda T. R. Huber N. Guanciale K. Perez-Tilve D. Habegger K. Ottaway N. et al. 2010 CNS leptin action modulates immune response and survival in sepsis. J Neurosci, 30 17 6036 6047 .
  63. 63. Finck B. N. Kelley K. W. Dantzer R. Johnson R. W. 1998 In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. Endocrinology, 139 5 2278 2283 .
  64. 64. Langouche L. Vander Perre. S. Frystyk J. Flyvbjerg A. Hansen T. K. Van den Berghe G. 2009 Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care, 13(4):R112.
  65. 65. Anderson P. D. Mehta N. N. Wolfe M. L. Hinkle C. C. Pruscino L. Comiskey L. L. Tabita-Martinez J. Sellers K. F. Rickels M. R. Ahima R. S. et al. 2007 Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab, 92 6 2272 2279 .
  66. 66. Bornstein S. R. Licinio J. Tauchnitz R. Engelmann L. Negrao A. B. Gold P. Chrousos G. P. 1998 Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab, 83 1 280 283 .
  67. 67. Faggioni R. Fantuzzi G. Gabay C. Moser A. Dinarello C. A. Feingold K. R. Grunfeld C. 1999 Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol, 276(1 Pt 2):R136 142 .
  68. 68. Wang W. Poole B. Mitra A. Falk S. Fantuzzi G. Lucia S. Schrier R. 2004 Role of leptin deficiency in early acute renal failure during endotoxemia in ob/ob mice. J Am Soc Nephrol, 15 3 645 649 .
  69. 69. Haas P. Straub R. H. Bedoui S. Nave H. 2008 Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. Regul Pept, 151(1-3):26-34.
  70. 70. Scherer P. E. Williams S. Fogliano M. Baldini G. Lodish H. F. 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 270 45 26746 26749 .
  71. 71. Wajchenberg B.L. 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev, 21 6 697 738 .
  72. 72. Koch A. Sanson E. Voigt S. Helm A. Trautwein C. Tacke F. 2011 Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care, 26 2 166 174
  73. 73. Owecki M. 2009 Fat tissue and adiponectin: new players in critical care? Crit Care, 13(4):174.
  74. 74. Kern P. A. Di Gregorio G. B. Lu T. Rassouli N. Ranganathan G. 2003 Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes, 52 7 1779 1785 .
  75. 75. Yamamoto Y. Hirose H. Saito I. Tomita M. Taniyama M. Matsubara K. Okazaki Y. Ishii T. Nishikai K. Saruta T. 2002 Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond), 103 2 137 142 .
  76. 76. Berg A. H. Combs T. P. Du X. Brownlee M. Scherer P. E. 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 7 8 947 953 .
  77. 77. Cawthorn W. P. Sethi J. K. 2008 TNF-alpha and adipocyte biology. FEBS Lett, 582 1 117 131 .
  78. 78. Wulster-Radcliffe M. C. Ajuwon K. M. Wang J. Christian J. A. Spurlock M. E. 2004 Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun, 316 3 924 929 .
  79. 79. Uji Y. Yamamoto H. Tsuchihashi H. Maeda K. Funahashi T. Shimomura I. Shimizu T. Endo Y. Tani T. 2009 Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery, 145 5 550 557 .
  80. 80. Teoh H. Quan A. Bang K. W. Wang G. Lovren F. Vu V. Haitsma J. J. Szmitko P. E. Al-Omran M. Wang C. H. et al. 2008 Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab, 295(3):E658 664 .
  81. 81. Swarbrick M. M. Havel P. J. 2008 Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord, 6 2 87 102 .
  82. 82. Tsuchihashi H. Yamamoto H. Maeda K. Ugi S. Mori T. Shimizu T. Endo Y. Hanasawa K. Tani T. 2006 Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Surg Res, 134 2 348 353 .
  83. 83. Tacke F. Wustefeld T. Horn R. Luedde T. Srinivas Rao. A. Manns M. P. Trautwein C. Brabant G. 2005 High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol, 42 5 666 673 .
  84. 84. Chudek J. Adamczak M. Karkoszka H. Budzinski G. Ignacy W. Funahashi T. Matsuzawa Y. Cierpka L. Kokot F. Wiecek A. 2003 Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc, 35 6 2186 2189 .
  85. 85. Yuan G. Chen X. Ma Qiao Q. Li J. Li R. Li X. Tang S. Zhou J. Song L. et H. et al. 2007 C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol, 194 2 275 281 .
  86. 86. Smith F. R. Goodman D. S. 1971 The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. J Clin Invest, 50 11 2426 2436 .
  87. 87. von Eynatten. M. Humpert P. M. 2008 Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn, 8 3 289 299 .
  88. 88. Wolf 2007 2007. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev, 65 5 251 256 .
  89. 89. Graham T. E. Yang Q. Bluher M. Hammarstedt A. Ciaraldi T. P. Henry R. R. Wason C. J. Oberbach A. Jansson P. A. Smith U. et al. 2006 Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med, 354 24 2552 2563 .
  90. 90. Tacke F. Weiskirchen R. Trautwein C. 2008 Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis. Hepatology, 48 5 1724 1725 ; author reply 1725-1726.
  91. 91. Henze A. Frey S. K. Raila J. Tepel M. Scholze A. Pfeiffer A. F. Weickert M. O. Spranger J. Schweigert F. J. 2008 Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes,., 57 12 3323 3326 .
  92. 92. Koch A. Weiskirchen R. Sanson E. Zimmermann H. W. Voigt S. Duckers H. Trautwein C. Tacke F. 2010 Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care, 14(5):R179.
  93. 93. Ritchie R. F. Palomaki G. E. Neveux L. M. Navolotskaia O. Ledue T. B. Craig W. Y. 1999 Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal, 13 6 273 279 .
  94. 94. Vincent J. L. Moreno R. 2010 Clinical review: scoring systems in the critically ill. Crit Care, 14(2):207.
  95. 95. Pilz S. Mangge H. Obermayer-Pietsch B. Marz W. 2007 Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest, 30 2 138 144 .
  96. 96. Luk T. Malam Z. Marshall J. C. 2008 Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol, 83 4 804 816 .
  97. 97. Rongvaux A. Shea R. J. Mulks M. H. Gigot D. Urbain J. Leo O. Andris F. 2002 Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol, 32 11 3225 3234 .
  98. 98. Ziegler M. 2000 New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem, 267 6 1550 1564 .
  99. 99. Kitani T. Okuno S. Fujisawa H. 2003 Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett, 544(1-3):74 8 .
  100. 100. Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. Matsuki Y. Murakami M. Ichisaka T. Murakami H. et al. 2005 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307 5708 426 430 .
  101. 101. Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. Matsuki Y. Murakami M. Ichisaka T. et al. Murakami H. 2007 Retraction. Science, 318(5850):565.
  102. 102. Xie H. Tang S. Y. Luo X. H. Huang J. Cui R. R. Yuan L. Q. Zhou H. D. Wu X. P. Liao E. Y. 2007 Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int, 80 3 201 210 .
  103. 103. Chen M. P. Chung F. M. Chang D. M. Tsai J. C. Huang H. F. Shin S. J. Lee Y. J. 2006 Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab, 91 1 295 299 .
  104. 104. Haider D. G. Schindler K. Schaller G. Prager G. Wolzt M. Ludvik B. 2006 Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab, 91 4 1578 1581 .
  105. 105. Sandeep S. Velmurugan K. Deepa R. Mohan V. 2007 Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism, 56(4):565 570 .
  106. 106. Samal B. Sun Y. Stearns G. Xie C. Suggs S. Mc Niece I. 1994 Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol, 14 2 1431 1437 .
  107. 107. Jia S. H. Li Y. Parodo J. Kapus A. Fan L. Rotstein O. D. Marshall J. C. 2004 Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest, 113 9 1318 1327 .
  108. 108. Weiss S. J. 1989 Tissue destruction by neutrophils. N Engl J Med, 320 6 365 376 .
  109. 109. Ognjanovic S. Bao S. Yamamoto S. Y. Garibay-Tupas J. Samal B. Bryant-Greenwood G. D. 2001 Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol, 26 2 107 117 .
  110. 110. Moschen A. R. Kaser A. Enrich B. Mosheimer B. Theurl M. Niederegger H. Tilg H. 2007 Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 178 3 1748 1758 .
  111. 111. Garcia J. G. Moreno Vinasco. L. 2006 Genomic insights into acute inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol, 291(6):L1113 1117 .
  112. 112. Martin P. R. Shea R. J. Mulks M. H. 2001 Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol, 183 4 1168 1174 .
  113. 113. Muller W. E. Perovic S. Wilkesman J. Kruse M. Muller I. M. Batel R. 1999 Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). DNA Cell Biol, 18 12 885 893 .
  114. 114. Fujiki K. Shin D. H. Nakao M. Yano T. 2000 Molecular cloning and expression analysis of the putative carp (Cyprinus carpio) pre-B cell enhancing factor. Fish Shellfish Immunol, 10 4 383 385 .
  115. 115. Mc Glothlin J. R. Gao L. Lavoie T. Simon B. A. Easley R. B. Ma S. F. Rumala B. B. Garcia J. G. Ye S. Q. 2005 Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet, 43(3-4):127-141.
  116. 116. Costa J. V. Duarte J. S. 2006 [Adipose tissue and adipokines]. Acta Med Port, 19 3 251 256 .
  117. 117. Spiegelman B. M. Frank M. Green H. 1983 Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem, 258 16 10083 10089 .
  118. 118. Niemann M. A. Bhown A. S. Bennett J. C. Volanakis J. E. 1984 Amino acid sequence of human D of the alternative complement pathway. Biochemistry, 23 11 2482 2486 .
  119. 119. Lesavre P. H. Hugli T. E. Esser A. F. Muller-Eberhard H. J. 1979 The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol, 123 2 529 534 .
  120. 120. Liu B. Zhang J. Tan P. Y. Hsu D. Blom A. M. Leong B. Sethi S. Ho B. Ding J. L. Thiagarajan P. S. 2011 A computational and experimental study of the regulatory mechanisms of the complement system. PLoS Comput Biol, 7(1):e1001059.
  121. 121. Whaley K. 1980 Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med, 151 3 501 516 .
  122. 122. Sprong T. Roos D. Weemaes C. Neeleman C. Geesing C. L. Mollnes T. E. van Deuren M. 2006 Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood, 107 12 4865 4870 .
  123. 123. Hiemstra P. S. Langeler E. Compier B. Keepers Y. Leijh P. C. van den Barselaar. M. T. Overbosch D. Daha M. R. 1989 Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest, 84 6 1957 1961 .
  124. 124. Flier J. S. Cook K. S. Usher P. Spiegelman B. M. 1987 Severely impaired adipsin expression in genetic and acquired obesity. Science, 237 4813 405 408 .Rosen B.S, Cook K.S, Yaglom J, Groves D.L, Volanakis J.E, Damm D, White T, Spiegelman B.M: 1989. Adipsin and complement factor D activity: an immune-related defect in obesity. Science, 244(4911):1483-1487.

Written By

Arjuna P. De Silva

Submitted: 07 April 2011 Published: 21 November 2011